KALA Bio Inc. News Releases

KALA BIO Announces Reverse Stock Split

Thu, 12 Nov 2026 08:00:00 -0500

Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026 Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock"), at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The...

KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results

Mon, 09 Nov 2026 08:00:00 -0500

New York, New York--(Newsfile Corp. - November 9, 2026) - KALA BIO, Inc. (NASDAQ: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026.Preliminary Third Quarter 2026 ResultsNet loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025.Net loss of approximately $4.0 million for the nine months ended September 30, 2026, compared to $27.7 million for the same period in 2025.Cash, cash...

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Tue, 29 Sep 2026 07:30:00 -0400

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key HighlightsTarget generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positiveProposed purchase price of approximately $15 million, payable in cash and...